Miro Sciences Pitches Stem Cell Therapy for Severe Crohn’s Disease
MSX: $0.052 +15.56% · MC: $16M
Miro Sciences’ investor presentation positions its StemSmart cell therapy for patients with severe Crohn’s disease who have failed existing treatments, and says the company is preparing for a planned Phase 2 trial in Australia and the United States. The presentation reports approximately $4 million in cash at the end of September and a market capitalisation of approximately $20 million as of November.

Comments